Exemestane
- Generic Name
- Exemestane
- Brand Names
- Aromasin
- Drug Type
- Small Molecule
- Chemical Formula
- C20H24O2
- CAS Number
- 107868-30-4
- Unique Ingredient Identifier
- NY22HMQ4BX
- Background
Exemestane is an oral steroidal aromatase inhibitor used in the adjuvant treatment of hormonally-responsive (also called hormone-receptor-positive, estrogen-responsive) breast cancer in postmenopausal women. It irreversibly binds to the active site of the enzyme resulting in permanent inhibition.
- Indication
For the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.
- Associated Conditions
- Stage I Breast Cancer, Refractory, advanced Breast cancer
The Effects of Short-term Preoperative Treatment With Hormonal Therapy on Gene Profiles in Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- Diagnostic Test: BlueprintDiagnostic Test: Mammaprint
- First Posted Date
- 2019-10-16
- Last Posted Date
- 2024-05-07
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 30
- Registration Number
- NCT04129216
- Locations
- 🇺🇸
Johns Hopkins Bayview Hospital, Baltimore, Maryland, United States
Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer
- Conditions
- Breast Cancer Metastatic
- Interventions
- First Posted Date
- 2019-08-16
- Last Posted Date
- 2025-01-27
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 367
- Registration Number
- NCT04059484
- Locations
- 🇺🇦
Investigational Site Number : 8040001, Kryvyi Rih, Ukraine
🇬🇷Investigational Site Number : 3000004, Thessaloniki, Greece
🇧🇷Hospital de Clinicas de Porto Alegre - HCPA Site Number : 0760001, Porto Alegre, Rio Grande Do Sul, Brazil
Breast Cancer Treatment Based on Organ-like Culture
- Conditions
- Breast Cancer Organoids
- Interventions
- Drug: PattozumabDrug: Ear particles
- First Posted Date
- 2019-04-24
- Last Posted Date
- 2019-04-24
- Lead Sponsor
- Xijing Hospital
- Target Recruit Count
- 300
- Registration Number
- NCT03925233
- Locations
- 🇨🇳
JingSu, Xi'an, Shaanxi, China
Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer
- Conditions
- Breast CancerHormone Receptor Positive Tumor
- Interventions
- First Posted Date
- 2019-03-14
- Last Posted Date
- 2022-05-31
- Target Recruit Count
- 17
- Registration Number
- NCT03874325
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis
- Conditions
- HER2/Neu NegativeProgesterone Receptor PositiveEstrogen Receptor PositiveMetastatic Breast CarcinomaAnatomic Stage IV Breast Cancer AJCC v8Metastatic Malignant Neoplasm in the BonePrognostic Stage IV Breast Cancer AJCC v8
- Interventions
- Radiation: Radiation Therapy
- First Posted Date
- 2018-10-01
- Last Posted Date
- 2025-02-17
- Lead Sponsor
- Emory University
- Target Recruit Count
- 36
- Registration Number
- NCT03691493
- Locations
- 🇺🇸
Grady Health System, Atlanta, Georgia, United States
🇺🇸Emory Saint Joseph's Hospital, Atlanta, Georgia, United States
🇺🇸Lewis Cancer and Research Pavilion at Saint Joseph's/Candler, Savannah, Georgia, United States
The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread
- Conditions
- Breast Neoplasms
- Interventions
- First Posted Date
- 2018-09-06
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 103
- Registration Number
- NCT03659136
- Locations
- 🇧🇪
Brussels - UNIV Saint-Luc, Bruxelles, Belgium
🇧🇪UZ Leuven, Leuven, Belgium
🇺🇸Cancer Treatment Centers of America at Western Regional Medical Center, Goodyear, Arizona, United States
Anti-hormonal Therapie With Ribociclib in HR-positive / HER2- Negative Metastatic Breast Cancer
- Conditions
- Breast Cancer Metastatic
- Interventions
- First Posted Date
- 2018-06-14
- Last Posted Date
- 2023-07-07
- Lead Sponsor
- German Breast Group
- Target Recruit Count
- 56
- Registration Number
- NCT03555877
- Locations
- 🇩🇪
Studienzentrum Onkologie Ravensburg, Ravensburg, Germany
T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer
- Conditions
- Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IIIB Breast Cancer AJCC v8Invasive Breast CarcinomaAnatomic Stage IV Breast Cancer AJCC v8HER2/Neu NegativeAnatomic Stage IIIC Breast Cancer AJCC v8Prognostic Stage IIIA Breast Cancer AJCC v8Prognostic Stage IIIC Breast Cancer AJCC v8Prognostic Stage III Breast Cancer AJCC v8Prognostic Stage IV Breast Cancer AJCC v8
- Interventions
- First Posted Date
- 2018-06-12
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 20
- Registration Number
- NCT03554044
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
Ph3 Study of Exemestane With or Without Entinostat in Chinese Patients With Hormone Receptor-Positive, Locally Advanced or Metastatic Breast Cancer
- First Posted Date
- 2018-05-29
- Last Posted Date
- 2021-07-09
- Lead Sponsor
- Taizhou EOC Pharma Co., Ltd.
- Target Recruit Count
- 375
- Registration Number
- NCT03538171
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy Medical Sciences, Beijing, Beijing, China
A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase Inhibitor
- Conditions
- Advanced Breast Cancer
- Interventions
- First Posted Date
- 2017-10-18
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 159
- Registration Number
- NCT03312738
- Locations
- 🇨🇳
Novartis Investigative Site, Wuhan, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.